Laverdia
Opinion
verdinexor
MedicineVeterinaryOpinion
Slovak is available via eTranslation, the European Commission's machine translation service.
Translate to Slovak | Important information about machine translation
On 5 November 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Laverdia film-coated tablets for dogs. The applicant for this veterinary medicinal product is Aniserve GmbH.
Laverdia is an anticancer veterinary medicinal product containing verdinexor (ATCvet code QL01XX92) as the active substance, which is a reversible, selective inhibitor of Chromosome Region Maintenance 1 (CRM1)-mediated nuclear export. By inhibiting CRM1, verdinexor prevents the export of Tumour Suppressor Proteins (TSP) and Growth Regulatory Proteins (GRP), allowing them to remain in the nucleus where they carry out their normal functions, potentially leading to anti-tumour effects.
The therapeutic benefit of Laverdia consists of increasing time to progression in dogs with stage II, III and IV lymphoma where use in a home setting is indicated. The most common side effects are anorexia, weight loss, lethargy, polydipsia, vomiting, diarrhoea, polyuria, pollakiuria, elevated alanine aminotransferase (ALT), elevated gamma-glutamyl transferase (GGT), elevated serum alkaline phosphatase (ALP), elevated blood urea nitrogen (BUN), elevated creatinine, thrombocytopenia.
The full indication is: ‘for increasing time to progression in dogs with stage II, III and IV lymphoma where use in a home setting is indicated’.
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Laverdia and therefore recommends the granting of the marketing authorisation.
Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.